TEST:

TriNetra™-Glio

This can offer valuable insights into diagnosis of suspected glial malignacies in cases where performing a biopsy is not possible. Moreover, molecular analysis of CGCs shows the potential in providing diagnostic insights that align with the current WHO classification system for the central nervous system.

"Datar Cancer Genetics Inc announced today that the US Food and Drug Administration (FDA) has granted 'Breakthrough Device Designation' for its 'TriNetra-Glio', a blood test to help in the diagnosis of brain tumors. This is the third test from the Company to have received the Breakthrough Device Designation from the US FDA. The Company's early-stage breast and prostate cancer detection tests became the first liquid biopsies to receive the Breakthrough Device Designation....A prospective, blinded study by a research team at the Imperial College, London, showed the test to be highly accurate. The test requires 15 ml blood and is indicated for patients where a brain biopsy, although necessary, cannot be performed or has been unsuccessful."